Conference Call with Mankind Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Mankind Pharma announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations at Rs 3,079 crore, up by 27% YoY Domestic revenue at Rs 2,544 crore, up 18% YoY, Exports at Rs 535 crore, up 100% YoY Adjusted EBITDA margin of 23.1% down by 120 bps YoY and PAT margin of 13.9% Diluted EPS of Rs 10.3 down by 12.5% YoY (FV Re.1) FY25 Financial Highlights: Revenue from Operations at Rs 12,207 crore, up by 19% YoY Domestic revenue at Rs 10,675 crore, up 13% YoY, Exports at Rs 1,532 crore, up 88% YoY Adjusted EBITDA margin of 25.9% up by 130 bps YoY and PAT margin of 16.4% Diluted EPS of Rs 49.1, up by 3% YoY (FV Re.1) Rajeev Juneja – Vice Chairman & Managing Director said, “Mankind’s revenue grew by 27% with adjusted EBITDA margins at ~23% in Q4 FY25 led by continued 1.3x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation. In FY25, reported revenue growth was 19% with adj. EBITDA margin of ~26% This has been a transformative year at Mankind with several strategic initiatives to ensure higher productivity and outperform IPM as seen in the past. BSV integration is progressing well with key focus on R&D;, improving MR productivity & scaling mandate brands across domestic & International business. During FY25, we’ve laid a strong foundation to deliver long-term sustainable growth led by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and high entry barrier super specialty portfolio of BSV.” Result PDF